Efficacy And Safety Of Macugen In Patients With Neovascular AMD In Routine Clinical Practice. (MACULA)

Pfizer logo

Pfizer

Status

Completed

Conditions

Neovascular Age-related Macular Degeneration

Treatments

Drug: pegaptanib sodium

Study type

Observational

Funder types

Industry

Identifiers

NCT00858208
A5751028

Details and patient eligibility

About

Efficacy and safety of MACUGEN in patients suffering from neovascular age-related macular degeneration in routine clinical practice at least as good as demonstrated in randomized multicenter clinical trials.

Full description

Eligible patients in routine clinical practice

Enrollment

86 patients

Sex

All

Ages

18 to 90 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

adults with neovascular age-related macula degeneration

Exclusion criteria

according to SmPC

Trial design

86 participants in 1 patient group

Patients with neovascular Age-Related Macula Degeneration
Treatment:
Drug: pegaptanib sodium

Trial contacts and locations

8

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems